- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05507372
Treatment for Post Acute COVID-19 Syndrome
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative viral pathogen leading to the COVID-19 pandemic. In 2022, after three successive waves of the pandemic, the majority of the human population has been exposed to the SARS-CoV-2 virus. During the two years since the pandemic ensued, multiple reports emerged of patients experiencing COVID-19 emergent symptoms lasting longer than 4 weeks since onset. Up to 15% of patients recovering from COVID-19 experience post-acute COVID-19 induced tinnitus .
To-date, post-acute COVID-19 tinnitus has not been treated successfully. As tinnitus may be related to SARS-CoV-2 neurological manifestations. This study aims to investigate if the dopamine receptor antagonist Pimozide can be used effectively treat COVID-19 induced tinnitus.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Andy Goren, MD
- Phone Number: 6507040850
- Email: andyg@appliedbiology.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosed with subjective tinnitus post COVID-19
- Tinnitus persists for at least 4 weeks
- Prior history of mild or no tinnitus
- 18 years or older
- Any gender
- Females of child bearing age must be on contraception
Exclusion Criteria:
- Pregnant
- Patients who participated in any interventional studies in the past 6 months
- Patients with severe hepatic impairment on admission (alanine aminotransferase higher than fivefold the upper limit)
- Patients taking any dopamine receptor antagonists
- Patient having history of hypersensitivity to Pimozide
- Patients unable to comply with the study schedule
- Actively using cortiocosteroids
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dopamine Receptor Modulator
Pimozide 1mg Oral
|
Dopamine Receptor Antagonist - Oral Pimozide
|
Placebo Comparator: Placebo
Placebo Oral
|
Dopamine Receptor Antagonist - Oral Pimozide
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tinnitus Handicap Inventory (THI)
Time Frame: 4 weeks
|
The Tinnitus Handicap Inventory Scale is between 0-100.
And is stratified to Grades between 1-5.
A higher grades means more severe handicap from tinnitus.
|
4 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: RAHUL RAJENDRA KUNKULOL, MBBS, DEPT.OF PHARMACOLOGY, RURAL MEDICAL COLLEGE, PIMS- DU (DU), LONI, PIN: 413736
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Otorhinolaryngologic Diseases
- Ear Diseases
- Sensation Disorders
- Hearing Disorders
- Tinnitus
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Dopamine Agents
- Dopamine Antagonists
- Anti-Dyskinesia Agents
- Pimozide
Other Study ID Numbers
- JW-COVID-DRG-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tinnitus, Subjective
-
State University of New York at BuffaloUniversity at BuffaloCompletedTinnitus, Subjective | Tinnitus | Noise Induced Tinnitus | Tinnitus, Objective | Tinnitus Aggravated | Tinnitus, Pulsatile | Tinnitus, Spontaneous Oto-Acoustic Emission | Tinnitus, Clicking | Tinnitus, Tensor Tympani InducedUnited States
-
Philipps University Marburg Medical CenterLinkoeping University; Eriksholm Research Centre; University Hospital of Gießen...CompletedTinnitus | Subjective Tinnitus | Chronic TinnitusGermany
-
Cairo UniversityRecruiting
-
University of ZurichRecruitingTinnitus, Subjective | TinnitusSwitzerland
-
Eye & ENT Hospital of Fudan UniversityNot yet recruiting
-
University of Illinois at Urbana-ChampaignGN Hearing A/SActive, not recruitingTinnitus, SubjectiveUnited States
-
University of ZurichCompletedTinnitus, SubjectiveGermany, Switzerland
-
Universiteit AntwerpenUniversity Hospital, AntwerpWithdrawnTinnitus, SubjectiveBelgium
-
Washington University School of MedicineNational Institute on Deafness and Other Communication Disorders (NIDCD)Completed
-
Merz Pharmaceuticals GmbHTerminatedSubjective TinnitusUnited States, United Kingdom, Poland, Austria, Belgium, Brazil, Czech Republic, France, Germany, Mexico, Netherlands, Portugal, South Africa, Spain
Clinical Trials on Pimozide 1 MG
-
University of CalgaryHotchkiss Brain Institute, University of CalgaryUnknownAmyotrophic Lateral Sclerosis (ALS)Canada
-
University of CalgaryBrain Canada; ALS CanadaUnknownAmyotrophic Lateral Sclerosis | ALSCanada
-
Aevi Genomic Medicine, LLC, a Cerecor companyCompletedAttention Deficit Disorder With HyperactivityUnited States
-
PfizerCompleted
-
Johnson & Johnson K.K. Medical CompanyCompleted
-
GlaxoSmithKlineCompleted
-
Bio Sidus SACompleted
-
National Center for Research Resources (NCRR)University of RochesterCompleted
-
Merck Sharp & Dohme LLCTerminatedAlzheimer's Disease | Amnestic Mild Cognitive Impairment | Prodromal Alzheimer's Disease
-
Galderma R&DCompletedHealthy Subjects, Male or Female, of 18-60 Years Old, With Phototype I, II or III, Not Pre-treated/Pre-protected SkinFrance